A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer

McHugh, DJ; Chudow, J; DeNunzio, M; Slovin, SF; Danila, DC; Morris, MJ; Scher, HI; Rathkopf, DE

Rathkopf, DE (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Genitourinary Oncol Serv, 1270 York Ave, New York, NY 10065 USA.

CLINICAL GENITOURINARY CANCER, 2020; 18 (3): 171

Abstract

In metastatic castration-resistant prostate cancer, poor single-agent response to Torc1 inhibition has been postulated to be, in part, due to release ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索